Shandong Buchang Pharmaceuticals Co Ltd
Shandong Buchang Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of medicines in China. It offers medicines to treat cardiac and cerebral vascular, urinary and digestive, respiratory, gynecological, and other diseases, as well as diabetes. The company was founded in 1993 and is based in Heze, China.
Shandong Buchang Pharmaceuticals Co Ltd (603858) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.014x
Based on the latest financial reports, Shandong Buchang Pharmaceuticals Co Ltd (603858) has a cash flow conversion efficiency ratio of -0.014x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-145.26 Million) by net assets (CN¥10.07 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Shandong Buchang Pharmaceuticals Co Ltd - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Shandong Buchang Pharmaceuticals Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Shandong Buchang Pharmaceuticals Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shandong Buchang Pharmaceuticals Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NeoGenomics Inc
NASDAQ:NEO
|
0.011x |
|
UNITIL Corporation
NYSE:UTL
|
0.026x |
|
SUFA Technology Industry Co Ltd CNNC
SHE:000777
|
0.002x |
|
Taiwan Fertilizer Co Ltd
TW:1722
|
0.023x |
|
Hyundai Wia
KO:011210
|
0.005x |
|
Lithium Argentina AG
NYSE:LAR
|
-0.008x |
|
Medicover AB
F:5M0B
|
0.118x |
|
Shandong Dongyue Organosilicon Mat
SHE:300821
|
0.023x |
Annual Cash Flow Conversion Efficiency for Shandong Buchang Pharmaceuticals Co Ltd (2011–2024)
The table below shows the annual cash flow conversion efficiency of Shandong Buchang Pharmaceuticals Co Ltd from 2011 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥9.81 Billion | CN¥939.95 Million | 0.096x | +763.71% |
| 2023-12-31 | CN¥11.38 Billion | CN¥-164.26 Million | -0.014x | -106.43% |
| 2022-12-31 | CN¥12.28 Billion | CN¥2.76 Billion | 0.224x | +145.65% |
| 2021-12-31 | CN¥14.45 Billion | CN¥1.32 Billion | 0.091x | -35.57% |
| 2020-12-31 | CN¥13.81 Billion | CN¥1.96 Billion | 0.142x | -25.40% |
| 2019-12-31 | CN¥13.79 Billion | CN¥2.62 Billion | 0.190x | +28.47% |
| 2018-12-31 | CN¥13.86 Billion | CN¥2.05 Billion | 0.148x | -0.30% |
| 2017-12-31 | CN¥13.22 Billion | CN¥1.96 Billion | 0.148x | +13.09% |
| 2016-12-31 | CN¥12.71 Billion | CN¥1.67 Billion | 0.131x | -55.07% |
| 2015-12-31 | CN¥7.26 Billion | CN¥2.12 Billion | 0.292x | -27.01% |
| 2014-12-31 | CN¥4.45 Billion | CN¥1.78 Billion | 0.400x | +53.90% |
| 2013-12-31 | CN¥4.28 Billion | CN¥1.11 Billion | 0.260x | -22.48% |
| 2012-12-31 | CN¥4.02 Billion | CN¥1.35 Billion | 0.335x | -39.43% |
| 2011-12-31 | CN¥2.80 Billion | CN¥1.55 Billion | 0.554x | -- |